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Summary
Objective: To investigate the effect of glucosamine on the loss of newly synthesized radiolabeled large and small proteoglycans by bovine
tendon, ligament and joint capsule.
Design: The kinetics of loss of 35S-labeled large and small proteoglycans from explant cultures of tendon, ligament and joint capsule treated
with 10 mM glucosamine was investigated over a 10-day culture period. The kinetics of loss of 35S-labeled small proteoglycans and the for-
mation of free [35S]sulfate were determined for the last 10 days of a 15-day culture period. The proteoglycan core proteins were analyzed by
gel electrophoresis followed by ﬂuorography. The metabolism of tendon, ligament and joint capsule explants exposed to 10 mM glucosamine
was evaluated by incorporation of [3H]serine and [35S]sulfate into protein and glycosaminoglycans, respectively.
Results: Glucosamine at 10 mM stimulated the loss of small proteoglycans from ligament explant cultures. This was due to the increased loss
of both macromolecular and free [35S]sulfate to the medium indicating that glucosamine affected the release of small proteoglycans as well as
their intracellular degradation. The degradation pattern of small proteoglycans in ligament was not affected by glucosamine. In contrast, glu-
cosamine did not have an effect on the loss of large or small proteoglycans from tendon and joint capsule or large proteoglycans from ligament
explant cultures. The metabolism of cells in tendon, ligament and joint capsule was not impaired by the presence of 10 mM glucosamine.
Conclusions: Glucosamine stimulated the loss of small proteoglycans from ligament but did not have an effect on small proteoglycan catab-
olism in joint capsule and tendon or large proteoglycan catabolism in ligament, tendon or synovial capsule. The consequences of glucosamine
therapy at clinically relevant concentrations on proteoglycan catabolism in joint ﬁbrous connective tissues need to be further assessed in an
animal model.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Fibrous connective tissues of the joint, namely joint capsule,
ligaments and tendons together allow for the articulation of
the synovial joint. Both joint capsule and ligaments stabilize
the joint and tendons transmit the force from the muscle to
the bone. Proteoglycans make up less than 3% of ﬁbrous
connective tissues of the joint1 nevertheless these macro-
molecules contribute to the structural integrity of these tis-
sues. The major proteoglycan in tensile regions of ﬁbrous
connective tissues is decorin at 80% of total proteogly-
cans present in the tissue. The remainder includes the large
aggregating proteoglycans, versican and aggrecan, and
other small leucine-rich proteoglycans including bigly-
can1e6. The small leucine-rich proteoglycans are involved
in the organization of ﬁbrillar collagen networks and the
large aggregating proteoglycans are believed to be involved
in the hydration of the tissue and separation of the collagen
ﬁbers. Type I collagen is the major component of ﬁbrous
connective tissues of the joint1,3,7. Furthermore complex
interactions between large and small proteoglycans and*Address correspondence and reprint requests to: Dr M. Z. Ilic,
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1501other collagenous and non-collagenous extracellular matrix
components have been documented in ﬁbrous connective
tissues in vivo and in vitro8,9.
Glucosamine is used as a chondroprotective agent in os-
teoarthritis to alleviate symptoms and disease progression.
There is, however, a controversy about the effectiveness of
glucosamine10 since some long term randomized clinical tri-
als of glucosamine treatment of patients with osteoarthritis
reported a reduction in joint space narrowing, osteophyte
score and pain which lead to a delay in joint replace-
ment10e12 and in other trials its effectiveness on joint
pain, function and stiffness was reported to be less convinc-
ing13,14. Some of these discrepancies have been attributed
to glucosamine preparations, dosages, trial designs and
sponsor bias10,13. Glucosamine has been postulated to af-
fect a number of anabolic and catabolic pathways in carti-
lage including the suppression of matrix degrading
enzymes, matrix metalloproteinases (MMPs) and aggreca-
nases (ADAMTS-4 and -5)15,16. Aggrecanases have been
implicated in the degradation of aggrecan in cartilage and
ﬁbrous connective tissues2,4,5,17e19. In ﬁbrous connective
tissues aggrecanases and MMPs have been implicated in
degradation of versican and may also play a role in degra-
dation of small leucine-rich proteoglycans2,4,5,20e24.
Previous studies have shown that glucosamine inhibited
stimulated aggrecan degradation and loss in explant cultures
of cartilage25e28. The mechanism by which glucosamine
1502 M. Z. Ilic et al.: Effect of glucosamine on proteoglycan loss in joint tissuesinhibits the stimulation of aggrecanase activity in cartilage is
not known, however, it has been reported to affect aggreca-
nase gene expression and activation15,25,28. Given that glu-
cosamine is used widely in treatment of osteoarthritis since
there is evidence to suggest that it has a potential to inhibit
proteoglycan catabolism in cartilage, its effects on joint tis-
sues other than cartilage have not been studied. The proteo-
glycans contribute to the functional properties of these
tissues and as in cartilage their metabolism is ﬁnely bal-
anced. A perturbation of this balance as a result of treatment
for diseased cartilage may have an adverse impact on the
health of joint ﬁbrous connective tissues. At present there
are no reports on the effect of glucosamine on the catabolism
and loss of proteoglycans in tendon, ligament and joint
capsule. This study investigates the effect of glucosamine
on the rates of loss of newly synthesized 35S-labeled large
aggregating and small leucine-rich proteoglycans from
tendon, ligament and joint capsule explant cultures and the
metabolism of these tissues.Materials and methods
Dulbecco’s modiﬁed Eagles medium (DMEM) containing 1 g/l (5.5 mM)
glucose, new born calf serum (NBCS), non-essential amino acids, penicillin
and streptomycin were purchased from CSL (Melbourne, Australia). Chon-
droitinase ABC (protease free from Proteus vulgaris; EC 4.2.2.4) was from
ICN Biomedicals Inc. (Costa Mesa, CA, USA). Carrier free [35S]sulfate in
aqueous solution and [3H]-L-serine were from DuPont New England Nuclear
(Boston, MA, USA). Glucosamine and keratanase (from Pseudomonas sp.;
EC 4.2.2.4) were from Sigma Chemical Co. (St. Louis, MO, USA). Amicon
Ultra-4 centrifugal ﬁlter devices with molecular weight cut off 10,000 were
from Millipore (Belford, MA, USA) and PD-10 columns were from Amersham
Biosciences (Sweden).EXPLANT CULTURES OF BOVINE TENDON, LIGAMENT
AND JOINT CAPSULEBovine deep ﬂexor tendon proximal to bifurcation (tensile region), collat-
eral ligament and joint capsule were dissected from a single metacarpopha-
langeal joint of a 1e3-year-old bovine. Tensile region of tendon was used in
this study since a change in the metabolism of proteoglycans has been sug-
gested to contribute to the altered composition of the extracellular matrix of
diseased tendon29,30. The synovial membrane and ﬁbrocartilagenous re-
gions were removed from macroscopically normal tissue3,31. Tissue pieces
were incubated in sulfate-free medium containing 200 mCi/ml of [35S]sulfate
for 6 h at 37C32. The tissue was washed with DMEM to remove unincorpo-
rated [35S]sulfate, then triplicate cultures containing 100 20 mg wet weight
tissue/4 ml medium were maintained in DMEM with or without 10 mM glucos-
amine for 10 days with daily change of medium. In this work 5.5 mM glucose
was present in the culture medium26,33. The spent medium was collected
and stored in the presence of proteinase inhibitors at 22C34. At the end
of the experiment the tissue was extracted with 4 ml 4 M guanidine hydro-
chloride buffered at pH 5.8 in the presence of proteinase inhibitors for 48 h
at 4C, followed by 4 ml 0.5 M NaOH for 24 h. For the measurements of turn-
over of large and small proteoglycans (see below), additional tissue cultures
were maintained for 0, 2, 4, 6, 8 and 10 days. In a separate experiment,
freshly dissected tendon, ligament and joint capsule were incubated with ra-
diolabeled sulfate as described above, and triplicate cultures of 100 20 mg
wet weight tissue/4 ml medium were maintained for 5 days in DMEM and
then continued in presence or absence of 10 mM glucosamine for another
10 days. The above experiments were performed at least three times with
tissue from different animals.MEASUREMENT OF TURNOVER OF 35S-LABELED
PROTEOGLYCANSMeasurement of turnover of total 35S-labeled proteoglycans
The radiolabeled macromolecules present in medium samples and in tis-
sue extracts were isolated on Sephadex G-25 columns (PD-10 columns) and
analyzed for radioactivity32,35. The percentage 35S-labeled proteoglycans re-
maining in the matrix on each day of culture was determined from the amount
of 35S-labeled macromolecules appearing in the medium on each day of cul-
ture and that remaining in the matrix at the end of the culture period as pre-
viously described36.Measurement of turnover of large and small 35S-labeled
proteoglycans
The rate of loss of large and small proteoglycan species from tissue with
time in culture was determined from the total 35S-radiolabeled macromolec-
ular content of tissue at the time of sampling (days 0, 2, 6, 8 and 10) and the
percentages of large or small proteoglycans present in the matrix at those
times, determined from gel chromatography of 4 M guanidinium chloride
matrix extracts on the column of Sepharose CL-4B. It was expressed as
a percentage of each species remaining in the matrix with time in culture
relative to that at the commencement of the treatment with glucosamine at
day 031,32,35.
Measurement of the rate of formation of [35S]sulfate and release
of 35S-labeled small proteoglycans
Explant cultures were maintained as triplicate samples in DMEM alone
for 5 days to allow time for the loss of 35S-labeled large proteoglycans
and unincorporated [35S]sulfate from the tissue prior to treatment with
10 mM glucosamine for further 10 days31,32,35.The radiolabeled small pro-
teoglycans present in medium samples on each day of treatment and in tis-
sue extracts were isolated on Sephadex G-25 columns (PD-10 columns)
and analyzed for radioactivity32,35. The data was plotted as cumulative re-
lease of 35S-labeled small proteoglycans into culture medium and percent-
age 35S-labeled small proteoglycans remaining in the matrix against
treatment period. In addition the amount of 35S radioactivity which eluted
in the total volume on Sephadex G-25 was determined for medium samples
for each day of treatment. This data was plotted as cumulative release of
free [35S]sulfate into medium during treatment period.MEASUREMENT OF PROTEIN AND PROTEOGLYCAN
SYNTHESISTendon, ligament and joint capsule, dissected from a single metacarpo-
phalangeal joint, were maintained in triplicate cultures (100 mg wet weight
tissue/4 ml medium) in presence or absence of 10 mM glucosamine for 7
days with daily change of medium. On day 7 of culture, the triplicate cultures
from each treatment were pre-incubated with 2 ml DMEM at 37C for 1 h.
The medium was then replaced with 2 ml DMEM containing 20 mCi [35S]sul-
fate/ml or 30 mCi [3H]serine/ml that was prepared as batch solution. Follow-
ing a 2 h incubation period, the 35S-radiolabeled tissue was extracted with
0.5 M NaOH for 24 h at room temperature and the [3H]serine radiolabeled
tissue was extracted by 4 M guanidinium chloride, 0.05 M sodium acetate,
pH 6 for 24 h at 4C followed by 0.5 M NaOH for 24 h at room temperature.
Radiolabeled macromolecules present in tissue extracts were separated
from unincorporated radiolabel by gel ﬁltration on PD-10 columns32,35.
The rate of incorporation of [35S]sulfate into proteoglycans and the rate of
incorporation of [3H]serine into protein were expressed as cpm/100 mg
wet weight tissue.ANALYSIS OF PROTEOGLYCAN CORE PROTEINSProteoglycans were isolated from pooled spent medium (days 0e5 and
6e10) and tissue (day 5) from ligament, tendon and joint capsule cultures
that were maintained in DMEM only for 5 days and then continued with or
without 10 mM glucosamine for further 5 days, by ion-exchange chromatog-
raphy as described previously37. Puriﬁed samples were concentrated and
exchanged into H2O containing proteinase inhibitors using Amicon
 Ultra-4
centrifugal ﬁlter devices with molecular weight cut off 10,000 as described
by the manufacturer, lyophilized and re-constituted in 0.1 M Tris/0.1 M so-
dium acetate, pH 7 and digested with chondroitinase ABC (0.025 U) and ker-
atanase (0.05 U) at 37C for 12 h in the presence of proteinase inhibitors34.
Digested samples were exchanged into H2O containing proteinase inhibitors
using the ﬁlter devices and lyophilized. Samples were subjected to electro-
phoresis on 4e15% gradient polyacrylamide/SDS slab gels. The gels were
ﬁxed and soaked in Amplify (Amersham Pharmacia, Buckinghamshire, UK)
for 20 min, dried and exposed to Kodak BioMax Light ﬁlm at 80C for
6e8 weeks.TREATMENT OF DATADue to the variation in the absolute metabolic measurements in joint con-
nective tissues from different animals any one experiment was restricted to
tissue obtained from a single joint38. Triplicate samples of tissue from a single
joint were analyzed and the meanSD was determined. Statistical signiﬁ-
cance was determined by Student’s t test. All experiments were repeated
at least three times (kinetics of loss of radiolabeled proteoglycans) or twice
(protein and proteoglycans synthesis) with tissue from different animals
and showed the same outcome.
1503Osteoarthritis and Cartilage Vol. 16, No. 12ResultsGLUCOSAMINE AFFECTED THE LOSS OF PROTEOGLYCANS
FROM LIGAMENT BUT NOT FROM TENDON OR JOINT
CAPSULE EXPLANT CULTURESFigure 1 shows the percentage of radiolabeled proteogly-
cans remaining in the matrix of tendon (A), ligament (C) and
joint capsule (E) over the 10-day culture period cultured with
or without 10 mM glucosamine. Glucosamine did not affect
the proteoglycan loss from the matrix of tendon and joint
capsule explants where approximately 35 and 60% of radio-
labeled proteoglycans were, respectively, lost from the tis-
sue after 10 days in culture with or without glucosamine.
However, glucosamine stimulated the loss of radiolabeled
proteoglycans from ligament explants from 41% in control
cultures to 60% by day 10 of culture.
The effect of glucosamine on the loss of large and small
radiolabeled proteoglycans is shown in Fig. 1 for tendon (B),
ligament (D) and joint capsule (F). Over 90% of radiolabeled
large proteoglycans was lost from the matrix of all three0
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Fig. 1. Glucosamine affects the kinetics of loss of 35S-labeled proteoglyca
sule explant cultures. Following the incubation of tissue with [35S]sulfate, t
of tendon, ligament or joint capsule maintained in culture for 10 days in the
in culture; (A, C, E) percentage of total (largeþ small) radiolabeled proteo
with 10 mM glucosamine (C); (B, D, F) percentage of radiolabeled large a
without (large proteoglycans, ,, small proteoglycans, 6), or with 10 mM
Values shown represent the mean of triplicate cultures of tissue from sam
by Student’stissues by day 10 of culture and this loss was not affected
by the presence of glucosamine. In ligament cultures glu-
cosamine stimulated the loss of small proteoglycans from
32% in control cultures to 52% by day 10 of culture
[Fig. 1(D)]. In contrast glucosamine did not affect the loss
of small proteoglycans from tendon and joint capsule ex-
plants showing approximately 27% and 51% loss of small
proteoglycans from the matrix, respectively, by day 10 of
culture [Fig. 1(B and F)].GLUCOSAMINE STIMULATED INTRACELLULAR DEGRADATION
AND THE LOSS OF SMALL PROTEOGLYCANS FROM
LIGAMENTIt has been shown previously that two metabolic path-
ways are responsible for the loss of small proteoglycans
from the matrix of ﬁbrous connective tissues. One involves
the cellular uptake and intracellular degradation of small
proteoglycans that results in the release of free sulfate to
the medium of explant cultures and the second one involves0 4 8 10
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B
D
F
Tendon
Ligament
Joint capsule
*
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ns from the matrix of bovine ligament but not tendon and joint cap-
he percentage of radiolabeled proteoglycans remaining in the matrix
presence or absence of 10 mM glucosamine is plotted against time
glycans remaining in the matrix of cultures cultured without (B), or
nd small proteoglycans remaining in the matrix of cultures cultured
glucosamine (large proteoglycans, -, small proteoglycans, :).
e animal and the SD (positive error bars). *P< 0.05 vs DMEM alone
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1504 M. Z. Ilic et al.: Effect of glucosamine on proteoglycan loss in joint tissuesa release of small proteoglycans and their fragments into
the medium of explant cultures32,35,39.
The effect of glucosamine on these two processes is
shown in Figs. 2e4 for tendon, ligament and joint capsule
explants, respectively, showing cumulative release of free
[35S]sulfate into the medium (A), cumulative release of
35S-labeled small proteoglycans into medium (B) and the
percentage of 35S-labeled proteoglycans remaining in the
matrix (C) with time in culture. In this experiment tissueDays in culture
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Fig. 2. Glucosamine does not have an effect of the rate of formation
of [35S]sulfate and the release of 35S-labeled small proteoglycans
from bovine tendon explant cultures. Following the incubation of tis-
sue with [35S]sulfate, tendon was maintained in DMEM for 5 days to
allow for the loss of majority of radiolabeled large proteoglycans
prior to treatment with 10 mM glucosamine for further 10 days.
The culture medium was collected daily and analyzed for the pres-
ence of [35S]sulfate and 35S-labeled small proteoglycans; (A) cumu-
lative release of [35S]sulfate into the culture medium for cultures
maintained without (>) or with glucosamine (¤); (B) cumulative re-
lease of 35S-labeled small proteoglycans into the culture medium for
cultures maintained without (6) or with glucosamine (:); (C) the
percentage of 35S-labeled small proteoglycans remaining in the
matrix with time in culture for cultures maintained without (6) or
with glucosamine (:). Values shown represent the mean of tripli-
cate cultures of tissue from same animal and the SD (positive error
bars).
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Fig. 3. Glucosamine affects the rate of formation of [35S]sulfate and
the release of 35S-labeled small proteoglycans from bovine liga-
ment explant cultures. Following the incubation of tissue with
[35S]sulfate, ligament was maintained in DMEM for 5 days to allow
for the loss of majority of radiolabeled large proteoglycans prior to
treatment with 10 mM glucosamine for further 10 days. The culture
medium was collected daily and analyzed for the presence of
[35S]sulfate and 35S-labeled small proteoglycans; (A) cumulative re-
lease of [35S]sulfate into the culture medium for cultures maintained
without (>) or with glucosamine (¤); (B) cumulative release of 35S-
labeled small proteoglycans into the culture medium for cultures
maintained without (6) or with glucosamine (:); (C) the percent-
age of 35S-labeled small proteoglycans remaining in the matrix
with time in culture for cultures maintained without (6) or with glu-
cosamine (:). Values shown represent the mean of triplicate cul-
tures of tissue from same animal and the SD (positive error bars).
*P< 0.05 vs DMEM alone by Student’s t test.was maintained in culture for 5 days after incubation with
[35S]sulfate to allow for the loss of the majority of radio-
labeled large proteoglycans [Fig. 1(BeF)] before the collec-
tion and analysis of samples in additional 10-day culture
period.
Glucosamine stimulated both pathways of loss of small
proteoglycans from ligament with over 100% increase in
the release of free [35S]sulfate and over 400% increase in
the release of 35S-labeled small proteoglycans into medium
[Fig. 3 (A and B)]. The majority (w92%) of total 35S-sulfated
molecules released into the medium of cultures in presence
of glucosamine were the radiolabeled macromolecules.
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Fig. 4. Glucosamine does not have an effect on the rate of forma-
tion of [35S]sulfate and the release of 35S-labeled small proteogly-
cans from bovine joint capsule explant cultures. Following the
incubation of tissue with [35S]sulfate, joint capsule was maintained
in DMEM for 5 days to allow for the loss of majority of radiolabeled
large proteoglycans prior to treatment with 10 mM glucosamine for
further 10 days. The culture medium was collected daily and ana-
lyzed for the presence of [35S]sulfate and 35S-labeled small proteo-
glycans; (A) cumulative release of [35S]sulfate into the culture
medium for cultures maintained without (>) or with glucosamine
(¤); (B) cumulative release of 35S-labeled small proteoglycans into
the culture medium for cultures maintained without (6) or with glu-
cosamine (:); (C) the percentage of 35S-labeled small proteogly-
cans remaining in the matrix with time in culture for cultures
maintained without (6) or with glucosamine (:). Values shown
represent the mean of triplicate cultures of tissue from same animal
and the SD (positive error bars).
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Fig. 5. Glucosamine does not have an effect on the proteolytic pro-
cessing of 35S-labeled small proteoglycans in ligament, tendon and
joint capsule explant cultures. Following the incubation of tissue
with [35S]sulfate, ligament, tendon and joint capsule were main-
tained in DMEM for 5 days to allow for the loss of majority of radio-
labeled large proteoglycans prior to treatment with 10 mM
glucosamine for further 5 days. A ﬂuorogram of 4e15% polyacryl-
amide/SDS gels shows radiolabeled small proteoglycan core pro-
teins that were isolated from the matrix of tendon (T), ligament (L)
and joint capsule (JC) on day 5 of culture period (aec) and from
the pooled medium from days 6 to 10 of culture period. Lane a: lig-
ament cultured in DMEM only; lanes b, c and d: ligament, tendon
and synovial capsule, respectively, cultured in the presence of glu-
cosamine. The weights of tissue (g) corresponding to the amount of
sample loaded on the gel were 0.2 g (panel A) and 0.4 g (panel B).
1505Osteoarthritis and Cartilage Vol. 16, No. 12Glucosamine did not affect either metabolic pathway of loss
of small proteoglycans in tendon and joint capsule cultures
(Figs. 2 and 4).GLUCOSAMINE DID NOT HAVE AN EFFECT ON THE
PROTEOLYTIC PROCESSING OF SMALL PROTEOGLYCANSThe major small proteoglycan present in tendon, ligament
and synovial capsule is decorin shown as the major radio-
labeled band ofw43 kDa (arrow) present in matrix and me-
dium of explants1e3,5. The same degradation pattern of
radiolabeled decorin isolated from the matrix of all threetissues [Fig. 5(A), aec] after 5 days in culture in DMEM
only suggests that the cleavage sites within decorin core
protein are identical in these tissues. The analysis of radio-
labeled decorin released to the culture medium in the ﬁrst 5
days of culture, however, shows a higher proportion of de-
corin fragments relative to intact decori released into the
medium of ligament than of tendon and joint capsule cul-
tures [Fig. 5(A), def]. The smaller molecular weight bands
between 15 and 36 kDa have previously been shown to
be decorin fragments that retained decorin amino-terminus
in ligament and tendon and resulted from cleavages within
the leucine-rich repeats of the core protein2,5. The addition
of glucosamine did not affect decorin degradation pattern in
ligament [Fig. 5(B), a, b] or in tendon or joint capsule (data
not shown).GLUCOSAMINE DID NOT HAVE AN EFFECT ON CELL
METABOLISMThe effect of glucosamine on protein and proteoglycan
synthesis was investigated in order to determine whether
10 mM glucosamine affected the general metabolism of ten-
don, ligament and joint capsule.
Table I shows that the exposure to glucosamine for 7
days did not have a signiﬁcant effect on proteoglycan or
protein synthesis in tendon, ligament or joint capsule cul-
tures where only a small reduction (2e10%) in [35S]sulfate
and [3H]serine incorporation into macromolecules was ob-
served. Thus 10 mM glucosamine did not impair the
Table I
Incorporation of [35S]sulphate and [3H]serine into macromolecules
by bovine tendon, ligament and joint capsule explant cultures main-
tained in DMEM in the absence or presence of glucosamine
Culture condition [35S]Sulphate
incorporation
(cpm/100 mg wet
weight of tissue/2 h)
[35H]Serine
incorporation
(cpm/100 mg wet
weight of tissue/2 h)
Day 7 Day 7
Tendon
DMEM alone 62,947 5043* 143,449 7240*
DMEMþ 10 mM
glucosamine
56,956 5251 (90) 136,170 7320 (95)
Ligament
DMEM alone 70,896 6125* 250,456 9889*
DMEMþ 10 mM
glucosamine
69,814 4450 (98) 225,880 54181 (90)
Joint capsule
DMEM alone 61,459 5513* 281,874 9497*
DMEMþ 10 mM
glucosamine
58,649 1055 (95) 274,867 3156 (98)
Values shown represent the mean of triplicate cultures of tissue
from same animal and the SD. Values in parentheses are
expressed as a percentage of values observed for cultures main-
tained in DMEM alone.
*Not signiﬁcant vs DMEM alone by Student’s t test.
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this is in line with results reported for cartilage26.Discussion
This work shows that unlike in cartilage where glucos-
amine acts on the pathways responsible for generating
stimulated aggrecanase activity at either transcriptional
and/or activation levels, glucosamine at 10 mM, did not af-
fect the loss of large aggregating proteoglycans in explant
cultures of ligament, tendon or synovial capsule
[Fig. 1(B,D,F)]25e28. In addition there was no effect on the
proteolytic processing of large proteoglycans (data not
shown). ADAMTS-4 and-5 are expressed in joint ﬁbrous
connective tissues and one or both of these proteinases
may be responsible for the degradation of large aggregating
proteoglycans in these tissues2,4,18,20,40e43. The lack of
effect of glucosamine treatment in joint ﬁbrous connective
tissue explants is likely to be due to the difference in the
regulation of aggrecanase activity in these tissues com-
pared to cartilage. This difference in the regulation of aggre-
canase activity is indicated by: (1) the rates of loss of
radiolabeled large proteoglycans from tendon, ligament
and joint capsule in explant cultures cultured in the absence
of cytokines are higher (t1/2w 1.5 days
31,32,35) than those
reported for cartilage explants (t1/2> 8 days
37,44), (2) under
the same conditions, the high rates of loss of radiolabeled
and total large proteoglycans are associated with extensive
proteolysis of the core proteins unlike in cartilage where the
extensive proteolysis of the core protein occurs in the pres-
ence of cytokines such as interleukin-1, tumour necrosis
factor a or retinoic acid2,4,5,31,32,37,45, and (3) the catabolic
stimulators do not appear to affect large proteoglycan deg-
radation and loss from explants of joint ﬁbrous connective
tissues2,4,20.
Furthermore a higher proportion of degraded large aggre-
gating proteoglycans is observed in vivo in normal joint ﬁ-
brous connective tissues then in cartilage from animals ofsimilar age2,4,5,18,41,46. This may be a result of relatively
higher large proteoglycan degrading activity in joint ﬁbrous
connective tissues compared to cartilage and, unlike carti-
lage these tissues retain large proteoglycan fragments that
lack the hyaluronan binding G1 domain. Aggrecan degrada-
tion and loss in normal human cartilage is low since t1/2 for
aggrecan has been estimated to be in excess of 3 years
and that for G1 domain 25 years47. The large proteoglycans
turnover rates in vivo in joint ﬁbrous connective tissues are
not known, however, proteolytic processing of large proteo-
glycans in these tissues appear to be important for their
normal function and, therefore, any treatment that aims to in-
hibit aggrecanase activity in diseased cartilage may have an
adverse effect in joint ﬁbrous connective tissues where the
studies of tendon pathology indicate that large aggregating
proteoglycans accumulate in the extracellular matrix of dis-
eased tissue29,30,48. In addition, studies have shown that
the inhibition of matrix degrading enzymes caused joint stiff-
ness and promoted changes in the composition of joint ﬁ-
brous connective tissues49,50. In this context, this study
suggests that the beneﬁt of the use of glucosamine for treat-
ment of osteoarthritis is that it is not likely to affect the catab-
olism and loss of large aggregating proteoglycans from
ﬁbrous connective tissues of the synovial joint.
Decorin is the major proteoglycan present in the extra-
cellular matrix of joint ﬁbrous connective tissues and
represents 80% of newly synthesized 35S-labeled mac-
romolecules in these tissues3,31,32. Unlike large aggregat-
ing proteoglycans, radiolabeled decorin was lost from the
matrix of explants of joint ﬁbrous connective tissues at
a much slower rate, t1/2 10 days [Fig. 1(B,D,F)]. Similar
rates of decorin loss have been previously reported for
joint ﬁbrous connective tissues and cartilage31,32,35,51. In
this study the comparison of radiolabeled decorin appear-
ing in the medium of tendon, ligament and joint capsule
showed that mainly intact decorin was lost in tendon
and synovial capsule explant cultures while signiﬁcant
levels of decorin fragments were present in the medium
of ligament explants. Since previous studies have re-
ported that in tendon and ligament explant cultures over
50% of total decorin lost to the medium was fragmented
it appears that in ligament but not in tendon explant cul-
tures the newly synthesized radiolabeled decorin follows
a similar pattern of release to that of total decorin2,5.
The treatment with glucosamine did not inhibit degrada-
tion of radiolabeled decorin in ligament cultures (Fig. 5)
even though glucosamine has the potential to suppress
the expression and activation of MMPs including gelati-
nases which are reported to be the most likely enzymes
involved in degradation of decorin21,23,52,53. On the con-
trary glucosamine increased the rate of loss of radiola-
beled decorin in ligament cultures [t1/2¼ 6 days,
Fig. 1(D)]. It appears that glucosamine has acted at mul-
tiple pathways since it affected both mechanisms of loss
of radiolabeled decorin in ligament explants, the intracellu-
lar degradation and the release of decorin from the matrix.
The intracellular degradation pathway involves endocyto-
sis through speciﬁc decorin receptors, transfer to- and
degradation within- lysosomes39,54,55. The enhanced re-
lease by glucosamine of decorin into the medium of liga-
ment cultures is likely to involve the disruption of
interactions between decorin and other macromolecular
components in the extracellular matrix of this tissue. The
intermolecular interactions would have been further weak-
ened for radiolabeled decorin fragments that have been
generated at a higher rate in ligament than in tendon
and joint capsule cultures.
1507Osteoarthritis and Cartilage Vol. 16, No. 12In mature bovine articular cartilage cultures glucosamine
concentrations of between 5 and 10 mMwere needed to sup-
press stimulated aggrecan catabolism without affecting cell
metabolism26. In the work described in this paper using liga-
ment cultures, 5 mM glucosamine did not have a signiﬁcant
effect on proteoglycan loss from the tissue (data not shown).
Persiani et al. showed in humans with osteoarthritis that
a therapeutic dose of glucosamine of 1500 mg/day leads to
a signiﬁcant increase in plasma (range 3.35e22.7 mM) and
synovial ﬂuid (range 3.22e18.1 mM) concentrations of this
amino sugar from the baseline of 0.25 mM and 0.21 mM, re-
spectively56. It should be emphasized that this work did not
take into account any glucosamine that was associated
with plasma proteins. At present it is not known what glucos-
amine concentration can be achieved within cartilage or joint
ﬁbrous connective tissues in vivo. Animal studies using ra-
diolabeled glucosamine have shown that the radioactivity
was taken up by articular cartilage57 and that the radiola-
beled glucosamine could originate from two distinct pools.
The ﬁrst was free glucosamine present in plasma that had
a fast clearance rate. The second radiolabeled pool of glu-
cosamine appeared in plasma 20 min after the animals
were administered glucosamine and the radioactivity was as-
sociated with the globulin protein fraction and had a long
clearance rate. Indeed, after repeated administration of ra-
diolabeled glucosamine 90% of the total radioactivity present
in plasma was associated with the protein fraction57. It has
been suggested that the radioactivity associated with the
globulin protein may represent a possible delivery pathway
of glucosamine to cells where it is released to cells by their
metabolic activity. However, it must be emphasized that the
nature of the radioactivity associated with the globulins has
yet to be characterized. The pool of glucosamine associated
with globulin proteins present in plasma was not taken into
account in the studies of Persiani et al.56. Furthermore,
high levels of glucosamine in joint tissues may be achieved
by derivatives of glucosamine, such as cell permeable lipo-
philic derivatives of glucosamine that are under investigation
as potential chondroprotective agents58.
In conclusion, glucosamine use as a therapeutic agent for
cartilage pathology is not likely to affect proteoglycan catab-
olism in joint ﬁbrous connective tissues, with the exception
of ligament where it may up-regulate the loss of decorin
from the matrix and thus affect the biomechanical properties
of this tissue. In recent paper it has also been reported that
glucosamine in conjunction with chondroitin sulfate stimu-
lates collagen synthesis in tendon but more so in ligament
cells59. Further studies using in vivo animal models are
needed to conﬁrm these effects.Conﬂicts of interest
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